Dishman Carbogen Amcis Limited (DCAL.NS)
INR 208.21
(-3.35%)
INR 208.21
(-3.35%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -413 Million INR | -116.05% |
| 2022 | 1.51 Billion INR | 28.03% |
| 2021 | 1.18 Billion INR | 67.14% |
| 2020 | 709.1 Million INR | -77.94% |
| 2019 | 3.21 Billion INR | -4.23% |
| 2018 | 3.35 Billion INR | 33.58% |
| 2017 | 2.51 Billion INR | 1.45% |
| 2016 | 2.47 Billion INR | -18.13% |
| 2015 | 3.02 Billion INR | 73.32% |
| 2014 | 1.74 Billion INR | -20.63% |
| 2013 | 2.19 Billion INR | 4.54% |
| 2012 | 2.1 Billion INR | 33.43% |
| 2011 | 1.57 Billion INR | 17.94% |
| 2010 | 1.33 Billion INR | -6.79% |
| 2009 | 1.43 Billion INR | -27.41% |
| 2008 | 1.97 Billion INR | 86.97% |
| 2007 | 1.05 Billion INR | 18.99% |
| 2006 | 888.01 Million INR | 68.36% |
| 2005 | 527.44 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -470.6 Million INR | -110.84% |
| 2023 Q2 | -57.2 Million INR | -111.13% |
| 2023 Q1 | 514.1 Million INR | 392.93% |
| 2023 FY | -243.6 Million INR | -116.05% |
| 2023 Q4 | -223.2 Million INR | -160.15% |
| 2023 Q3 | 371.1 Million INR | 748.78% |
| 2022 FY | 1.51 Billion INR | 28.03% |
| 2022 Q1 | 132.1 Million INR | 121.35% |
| 2022 Q2 | 78.8 Million INR | -40.35% |
| 2022 Q4 | -175.5 Million INR | -125.06% |
| 2022 Q3 | 700.4 Million INR | 788.83% |
| 2021 Q4 | -618.8 Million INR | -279.1% |
| 2021 FY | 1.18 Billion INR | 67.14% |
| 2021 Q2 | 251.8 Million INR | -2.89% |
| 2021 Q1 | 259.3 Million INR | -21.16% |
| 2021 Q3 | 345.5 Million INR | 37.21% |
| 2020 FY | 709.1 Million INR | -77.94% |
| 2020 Q4 | 328.9 Million INR | 299.7% |
| 2020 Q3 | -164.7 Million INR | -1098.18% |
| 2020 Q2 | 16.5 Million INR | 110.5% |
| 2020 Q1 | -157.1 Million INR | -120.46% |
| 2019 Q1 | 521.6 Million INR | -57.39% |
| 2019 FY | 3.21 Billion INR | -4.23% |
| 2019 Q2 | 757.8 Million INR | 45.28% |
| 2019 Q4 | 768 Million INR | 44.14% |
| 2019 Q3 | 532.8 Million INR | -29.69% |
| 2018 Q3 | 750.5 Million INR | 5.57% |
| 2018 Q2 | 710.9 Million INR | 6.66% |
| 2018 Q1 | 666.5 Million INR | -5.68% |
| 2018 Q4 | 1.22 Billion INR | 63.09% |
| 2018 FY | 3.35 Billion INR | 33.58% |
| 2017 Q4 | 706.6 Million INR | 6.67% |
| 2017 FY | 2.51 Billion INR | 1.45% |
| 2017 Q3 | 662.4 Million INR | -15.53% |
| 2017 Q2 | 784.2 Million INR | 321.39% |
| 2017 Q1 | 186.1 Million INR | -79.25% |
| 2016 Q1 | 737 Million INR | 66.07% |
| 2016 Q2 | 848.9 Million INR | 15.18% |
| 2016 Q4 | 897 Million INR | 35.01% |
| 2016 Q3 | 664.4 Million INR | -21.73% |
| 2016 FY | 2.47 Billion INR | -18.13% |
| 2015 Q3 | 828.97 Million INR | 26.79% |
| 2015 Q4 | 443.8 Million INR | -46.46% |
| 2015 FY | 3.02 Billion INR | 73.32% |
| 2015 Q1 | 784.97 Million INR | 376.83% |
| 2015 Q2 | 653.83 Million INR | -16.71% |
| 2014 Q4 | 164.62 Million INR | -66.02% |
| 2014 Q3 | 484.52 Million INR | -24.01% |
| 2014 Q1 | 448.58 Million INR | -18.02% |
| 2014 Q2 | 637.63 Million INR | 42.14% |
| 2014 FY | 1.74 Billion INR | -20.63% |
| 2013 Q4 | 547.21 Million INR | 55.85% |
| 2013 Q3 | 351.1 Million INR | -49.55% |
| 2013 Q2 | 695.94 Million INR | 15.06% |
| 2013 Q1 | 604.85 Million INR | 8.48% |
| 2013 FY | 2.19 Billion INR | 4.54% |
| 2012 Q3 | 436.9 Million INR | -4.2% |
| 2012 Q4 | 557.58 Million INR | 27.62% |
| 2012 Q1 | 653.02 Million INR | -11.88% |
| 2012 FY | 2.1 Billion INR | 33.43% |
| 2012 Q2 | 456.07 Million INR | -30.16% |
| 2011 Q4 | 741.02 Million INR | 145.69% |
| 2011 Q3 | 301.6 Million INR | 0.0% |
| 2011 FY | 1.57 Billion INR | 17.94% |
| 2010 FY | 1.33 Billion INR | -6.79% |
| 2009 FY | 1.43 Billion INR | -27.41% |
| 2008 FY | 1.97 Billion INR | 86.97% |
| 2007 FY | 1.05 Billion INR | 18.99% |
| 2006 FY | 888.01 Million INR | 68.36% |
| 2005 FY | 527.44 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Biocon Limited | 50.83 Billion INR | 100.812% |
| Blue Jet Healthcare Limited | 3.37 Billion INR | 112.247% |
| Concord Biotech Limited | 6.26 Billion INR | 106.595% |
| Jubilant Ingrevia Limited | 2.93 Billion INR | 114.048% |
| Lyka Labs Limited | 29.13 Million INR | 1517.782% |
| Panacea Biotec Limited | - INR | Infinity% |
| Piramal Pharma Limited | 4.31 Billion INR | 109.571% |
| SMS Lifesciences India Limited | 359.47 Million INR | 214.891% |
| Supriya Lifescience Limited | 1.57 Billion INR | 126.278% |
| Syngene International Limited | 6.46 Billion INR | 106.385% |
| TAKE Solutions Limited | -213.49 Million INR | -93.452% |
| Zota Health Care Limited | -129.79 Million INR | -218.192% |